Loading company…
Pepticom Ltd. uses AI to develop peptide therapeutics, starting with an oral IL-17 inhibitor for plaque psoriasis.
Founded in 2011 in Jerusalem, Israel, Pepticom Ltd. designs and optimizes therapeutic peptides with a computational AI platform that uses reinforcement learning. Its lead focus is plaque psoriasis, treated with an oral IL-17 inhibitor. It works with pharmaceutical companies through partnerships, licensing and milestone-based payments. The company has completed 3 deals, the latest a USD 6.6 mn Series A led by Japan-Israel Hi-Tech Ventures on January 7, 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in